INTRODUCTION
============

Spectrum of Neurocognitive Impairment in Cirrhosis spans the range from normal cognitive function to minimal hepatic encephalopathy (MHE) to overt hepatic encephalopathy (OHE).^[@bib1],\ [@bib2]^ Cerebral edema is associated with HE both in patients with acute liver failure and with cirrhosis. However, in acute liver failure, cerebral edema develops rapidly and does not allow the system to compensate to counteract the osmotic imbalance induced by rapid intra-astrocytic accumulation of glutamine, while in cirrhosis there is sufficient time for effective compensation and stabilization of osmolyte shift.^[@bib3]^ Intracranial hypertension develops in 80% of patients with acute liver failure and leads to 25% mortality, while intracranial hypertension is rarely observed in patients with cirrhosis, even though cerebral edema may be present.^[@bib4]^

Although MHE is seen in 30--80% of patients with cirrhosis of liver, OHE occurs in approximately 30--45% of patients with cirrhosis.^[@bib2],\ [@bib5]^ Both MHE and OHE are considered to be fully reversible with treatment.^[@bib6]^ The burden and impact of MHE is significant. MHE impairs daily functioning and health-related quality of life, predicts the development of OHE, and is associated with poor survival,^[@bib6],\ [@bib7],\ [@bib8]^ impaired driving skills, increased number of traffic violations and even crashes.^[@bib9]^ Psychometric hepatic encephalopathy score (PHES) is a reliable tool for the diagnosis of MHE, has been validated, and has a high sensitivity (96%) and specificity (100%).^[@bib8],\ [@bib10]^ However, these tests do not reveal the underlying pathophysiology.

Brain magnetic resonance imaging (MRI) reveals characteristic findings in HE and may complement neuropsychological (NP) examination. Classic MRI abnormalities include high signal intensity in the globus pallidus on T1-weighted images, likely a reflection of increased tissue concentrations of manganese. An elevated glutamine/glutamate peak coupled with decreased myo-inositol and choline signals on proton MR spectroscopy (MRS) represents disturbances in cell-volume homeostasis secondary to brain hyperammonemia. Recent data have demonstrated that low-grade cerebral edema can be detected with several MR techniques such as magnetization transfer ratio (MTR) measurements, fast fluid-attenuated inversion recovery (FLAIR) sequences, diffusion-weighted images (DWI), and diffusion tensor imaging (DTI). All these MRI abnormalities, which return to normal with restoration of liver function, probably reflect the presence of mild diffuse cerebral edema, which seems to have an essential role in the pathogenesis of HE in cirrhosis.^[@bib11]^ MTR is relatively simpler and useful technique to detect low-grade cerebral edema in HE, which may not be visible by using standard MRI and is mainly based on the interaction between protons in a relatively free environment (bulk water) and those in which motion is restricted (immobile water).

Although the evidence base supporting a pivotal role of ammonia is robust, in everyday clinical practice a consistent correlation between the concentration of ammonia in the blood and the manifest symptom HE is not observed. More recently, the synergistic role of inflammation and infection in modulating the cerebral effects of ammonia has shown to be important.^[@bib12],\ [@bib13]^ It has been recognized that infection impairs brain function both in the presence and absence of liver disease. Thus it could be postulated that, in the presence of ammonia, the brain is sensitized to a systemic inflammatory stimulus and is able to elicit an inflammatory response involving both pro-inflammatory and neurotransmitter pathways.^[@bib12],\ [@bib13]^

Studies of MTR in MHE are limited and its correlations with ammonia and inflammatory mediators have not been studied thus far. This study was undertaken to assess the presence of low-grade cerebral edema as assessed by MTR in patients with MHE and its reversibility following treatment of MHE. To understand the pathophysiology of cerebral edema in MHE, we also assessed the correlation of inflammatory markers such as interleukin (IL)-1, IL-6 and tumor necrosis factor alpha (TNF-α) and ammonia with cerebral edema.

METHODS
=======

The Ethics Committee of Postgraduate Institute of Medical Education and Research (PGIMER), a tertiary level health-care center in Chandigarh, India approved the study (Endst number 1Trg-PG-2012/5053, dated 19 April 2014). Each subject gave written informed consent before being included in the study. The guidelines laid down by Indian Council of Medical Research (1994) and Helsinki declarations (modified in 1989) were adhered to in all patients in the study.

Patients
--------

All patients diagnosed to have cirrhosis of liver attending the outpatient liver clinic as well as those admitted under Hepatology services, PGIMER, Chandigarh were candidates for enrollment. The diagnosis of cirrhosis was based on clinical, biochemical, and ultrasonographic or liver histological data. Exclusion criteria were OHE; alcohol intake during the past 6 weeks; history of gastrointestinal bleed in the past 6 weeks; active ongoing sepsis; history of porto-systemic shunt surgery or transjugular intrahepatic portosystemic shunt; significant co-morbid illness such as heart, respiratory, or renal failure, any neurological diseases such as Alzheimer\'s disease, Parkinson\'s disease, non-hepatic metabolic encephalopathies and stroke; patients on psychoactive drugs such as antidepressants or sedatives; those who restarted alcohol consumption during follow-up; serum creatinine \>1.5 mg; electrolyte imbalance; hepatocellular carcinoma; contra-indications to MRI; inability to perform PHES; and unable to give informed consent. Etiology of cirrhosis of liver was determined as described previously.^[@bib6]^

Six age- and sex-matched healthy volunteers were included in the study for comparison.

Clinical and laboratory assessment
----------------------------------

All included patients underwent a thorough general physical and systemic examination, including complete neurological examination to exclude the presence of any illness which can affect the neurological status. Laboratory investigations included a complete hemogram, serum electrolytes, renal and liver function tests, and complete coagulogram. The severity of cirrhosis was determined by Child--Pugh\'s and model for end-stage liver disease scores. Ultrasound of abdomen and upper gastrointestinal endoscopy was performed in all patients. Triphasic contrast enhanced computed tomography of the abdomen was carried out in all patients; one patient demonstrated spontaneous leno-renal portosystemic shunt. Evidence for systemic inflammatory response syndrome (SIRS) was assessed in all patients at enrollment into the study.

NP assessment
-------------

The West Haven grade=0, a mini mental state examination score ≥25 and Clinical Hepatic Encephalopathy Staging Scale=0 determined grade 0 HE in patients with cirrhosis.^[@bib1],\ [@bib14],\ [@bib15]^ NP assessment was done by PHES. PHES has been validated for the assessment of MHE in an Indian population and can be carried out in 15--20 min.^[@bib8]^ The clinical significance of the PHES has also been evaluated in a large number of healthy volunteers and patients with MHE.^[@bib8],\ [@bib16]^ PHES ≤−5 was considered to be diagnostic of MHE.^[@bib8]^

Neuroimaging
------------

Whole-brain conventional MRI, including T2, FLAIR, and DWI in axial planes and T1 MPRAGE (magnetization-prepared rapid gradient echo) or SPGR (spoiled gradient recalled acquisition in steady state), was performed on a 3.0 Tesla MR scanner (Verio, Siemens Medical Solutions, Erlangen, Germany or GE Healthcare, Waukesha, WI). Subsequently MTR was performed. The MR findings were analyzed by two observers (C.K.A. and N. Kalra) blinded to the clinical and biochemical characteristics and levels of inflammatory mediators. The total examination time was approximately 20 min in each subject. T2-weighted images (repetition time (TR)=9000 ms; echo-time (TE)=94 ms; matrix size=320 × 320; field of view (FOV)=220 × 220 mm^2^; slice thickness=4.0 mm; interslice gap=0.0 mm; turbo factor=5; flip angle (FA)=158°) were acquired in the axial plane covering whole brain. High-resolution T1-weighted images were collected using a SPGR or MPRAGE sequence (TR=1800 ms; TE=3.87 ms; inversion time=900 ms; FA=9° matrix size=256 × 100; FOV=230 × 230 mm; slice thickness=1 mm and transverse imaging plane). Magnetization transfer imaging study was performed in the transverse plane before and after application of a proton saturation pulse. MTR values were quantified as a percentage of signal loss according to the following equation: MTR=100(S0−SS)/S0 in which S0 is the mean signal intensity for a particular region without the saturation pulse and SS is the mean signal intensity for the same region with saturation pulse. The mean MTRs were determined in regions of interest (ROIs) manually drawn by one examiner (C.K.A.), placed in the right and left frontal white matter (FWM); right and left parietal white matter (PWM); right and left internal capsule (IC) (average of anterior limb, genu, and posterior limb of IC on each side); and right and left basal ganglia (BG). MTR values were reported as a mean of right and left ROIs. ROI size was kept constant for all regions.

Blood samples analysis
----------------------

Blood samples from a peripheral vein were collected at baseline and after 8 weeks of the follow-up. Blood sample analysis for ammonia and cytokines were performed as described by us previously.^[@bib17]^ Ammonia estimation was carried out immediately using the Ammonia Checker II (Daiichi Kagaku, Kyoto, Japan) using finger prick blood. Cytokines (TNF-α, IL-1β, and IL-6) were measured in plasma derived from patients with cirrhosis using a specific Enzyme-linked Immunosorbent Assay Kits (RayBiotech,Norcross, GA) according to the manufacturer\'s protocol. The plate was read at 450 nm. Absorbance was converted to pg/ml using a standard curve prepared with recombinant human TNF-α, IL-1β, and IL-6.

Study design
------------

Patients who met eligibility criteria were included in the study and underwent NP evaluation by PHES. PHES ≤−5 was diagnostic of MHE.^[@bib8]^ They were divided into two groups, i.e., MHE and NMHE based upon the results of PHES. Patients in each group were followed for 8 weeks. In the MHE group, patients received 30--60 ml of lactulose in 2 or 3 divided doses so that patient passed 2--3 semisoft stools per day and rifaximin 550 mg twice daily for 8 weeks. Clinical and standard laboratory assessment, ammonia, inflammatory mediators (IL-1, IL-6 and TNF-α), PHES, and MRI (T1, T2W images, and MTR) were analyzed in MHE and NMHE patients at baseline and at 8 weeks. Control subjects were also investigated in a similar manner at baseline.

Statistical analysis
--------------------

Data were expressed as mean (95% confidence interval) for normally distributed data and median for skewed data. One-way analysis of variance and *post-hoc* analysis was carried out to assess the trend of baseline parameters between various groups and to compute statistical significance between them. Categorical variables were compared using Chi square and Fisher exact tests. Continuous variables were compared using Mann--Whitney *U*-test for unpaired data and Wilcoxon signed-rank test for paired data. Spearman\'s rank correlation was used to explore the association between PHES scores, ammonia, inflammatory markers, and MTR indices. The probability level of \<0.05 was set for statistical significance. SPSS 17 (SPSS, Chicago, IL) was used for statistical computations.

RESULTS
=======

Between April 2012 and June 2013, 150 patients diagnosed to have cirrhosis of liver attending the outpatient liver clinic as well as those admitted under Hepatology services, PGIMER, Chandigarh were screened. Twenty-three patients (15.3%) who met the eligibility criteria were included in the study. Reasons that 127 patients (84.7%) were excluded from the study were: history of alcohol intake in the past 6 weeks (33 patients), hepatocellular carcinoma (13 patients), chronic kidney disease (4 patients), psychiatric/neurological disease (3 patients), need for long-term antibiotic use (6 patients), interferon treatment for hepatitis C virus (5 patients), spontaneous spleno-renal shunt (1patient), recent gastrointestinal bleed \<6 weeks (4 patients), serum sodium \<135 mEq/dl (23 patients), illiterate (10 patients), significant co-morbidities (3 patients), refusal to give consent for MRI brain or follow-up (25 patients), and unfit for MRI (4 patients). Several patients were excluded for more than one reason. After exclusion, 23 patients included in the study were screened with PHES: 14 (60.9%) patients were found to have MHE and 9 (39.1%) constituted the NMHE group. Patients found to have MHE were treated with rifaximin and lactulose as per protocol. During a follow-up of 8 weeks, 1 patient was lost to follow-up and 1 died (owing to spontaneous bacterial peritonitis resulting in sepsis and renal failure) in the NMHE group, while 1 patient was lost to follow-up and 6 died (1 owing to refractory gastrointestinal bleed, 2 owing to development of overt HE followed by sepsis and 3 owing to community-acquired infections resulting in sepsis and multi-organ failure) in the MHE group. Rest of the patients, 7 in each group, completed the study. [Figure 1](#fig1){ref-type="fig"} shows flow of participants into the study. The clinical and demographic characteristics of patients enrolled in the study are shown in [Table 1](#tbl1){ref-type="table"}. There was no statistically significant difference between patients completing and those not completing the study ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Ammonia and inflammatory markers
--------------------------------

Ammonia was significantly higher in the NMHE and MHE groups as compared with controls and was significantly higher in MHE when compared with NMHE ([Table 2](#tbl2){ref-type="table"}). Among inflammatory markers, IL-1 and IL-6 were significantly elevated in MHE patients when compared with controls. There was no significant difference in TNF-α level between any study groups. SIRS was present in 50% of patients of MHE and was not seen in controls or the NMHE group ([Table 2](#tbl2){ref-type="table"}).

In the cirrhosis group, PHES correlated negatively with ammonia levels (*r*=−0.502, *P*=0.015). Ammonia also had a significantly positive correlation with IL-1 and IL-6 in patients with cirrhosis (*r*=0.566, *P*=0.009 and *r*=0.473, *P*=0.030, respectively).

[Table 3](#tbl3){ref-type="table"} shows changes in ammonia and inflammatory mediators in the NMHE and MHE group at baseline and 8 weeks. Ammonia and inflammatory markers did not show any significant change in the NMHE and MHE group although IL-6 levels showed a trend in improvement during follow-up. PHES scores significantly improved in the MHE group after treatment but did not show any significant change on follow-up in the NMHE group.

MRI evaluation
--------------

Upon brain MRI, diffuse atrophy was seen in 47.9% of patients with liver cirrhosis. T1 sequence showed bilateral basal ganglion hyperintensities in 60.8% of patients with cirrhosis and were more common in the MHE group (78.6%) than in the NMHE group (33.3%) (*P*=0.077) although not statistically significant. T2 white matter hyperintensities were seen in 21.7% of patients with cirrhosis and were similar between patients with and without MHE (28.6% and 11.1%, respectively, *P*=0.611).

MTR values in FWM, PWM, IC, and BG were significantly lower in the MHE group when compared with controls (*P*=0.002, 0.002, 0.003 and 0.019, respectively). When the MHE group was compared with the NMHE group, MTR in all regions were significantly lower except in FWM (FWM, *P*=0.105; PWM, *P*=0.001; IC, *P*=0.013; and BG, *P*=0.031; [Table 4](#tbl4){ref-type="table"}).

In the MHE group at 8 weeks follow-up, there were significantly increased MTR values in all the brain regions studied except BG (FWM (*P*=0.028), PWM (*P*=0.043), and IC (*P*=0.028)), demonstrating improvement in cerebral edema. The 8-week MTR values were statistically not different from those of controls in all regions of the brain studied, suggesting that MHE patients improved to the level of controls with treatment. In the NMHE group, there were no significant changes in MTR values between baseline and follow-up ([Table 5](#tbl5){ref-type="table"}).

Correlations of ammonia, inflammatory markers and PHES scores with MTR
----------------------------------------------------------------------

IL-6 levels had significant negative correlations with MTR values in PWM and IC (*r*=−0.608, *P*=0.004 and *r*=−0.454, *P*=0.044, respectively) in patients with liver cirrhosis. Ammonia correlated negatively with MTR values of PWM only (*r*=−0.445, *P*=0.043). PHES correlated positively with MTR values in PWM (*r*=0.589, *P*=0.005) and IC (*r*=0.533, *P*=0.013). However, there was no significant correlation between changes in MTR values and changes in PHES, ammonia, or inflammatory markers levels after treatment in MHE patients ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

DISCUSSION
==========

This study demonstrated the presence of low-grade cerebral edema in patients with cirrhosis and MHE, which is reversible after the treatment with lactulose and rifaximin. We also demonstrated that there is a significant correlation between ammonia levels, inflammatory markers, and MTR at baseline in patients of cirrhosis with MHE. PHES also correlated with ammonia and MTR values. These finding suggests that inflammation and ammonia have a role to play in the genesis of low-grade cerebral edema in patients with MHE with a resultant cognitive decline.

Studies have shown that serum ammonia levels correlate with the severity of HE, with the highest ammonia levels seen in patients with grade 3/4 HE compared with grade 1/2 HE.^[@bib18]^ Arterial ammonia levels are significantly higher in patients with MHE than those without MHE and controls.^[@bib19]^ Our study also demonstrated that ammonia levels were significantly higher in the MHE than in the NMHE and control groups. However, Shawcross *et al.*^[@bib20]^ demonstrated that a consistent correlation between ammonia levels and severity of HE is not always observed and other factors such as inflammation may be involved in the pathogenesis of HE. They showed that inflammatory markers such as white cell count, C-reactive protein levels and IL-6 were significantly higher in those with MHE than in those without MHE.^[@bib21]^ Montoliu *et al.*^[@bib22]^ also demonstrated that IL-6 concentration was significantly higher in the MHE group compared with the NMHE group and in the NMHE group compared with controls with a good correlation of IL-6 with PHES. Jain *et al.*^[@bib19]^ showed that levels of inflammatory cytokines and arterial ammonia decreased significantly in MHE patients when treated with lactulose for 3 months. Fifty percent of our patients with MHE had SIRS in the absence of active infection compared with none in the NMHE and control groups. Also, markers of inflammation such as IL-1 and IL-6 levels were significantly higher in the MHE group compared with controls. A positive correlation between ammonia, IL-1, and IL-6 levels in patients of cirrhosis with or without MHE and a negative correlation between ammonia levels with composite PHES shows that with increasing levels of ammonia there is increasing level of inflammation and progressive deterioration of NP functions. These data together suggest a synergism of ammonia and inflammation in the pathogenesis of MHE and confirms previous observations.^[@bib23]^ Treatment with rifaximin and lactulose for 8 weeks in MHE patients resulted in reversal of cerebral edema coupled with improvement in PHES and a trend towards reduction in ammonia, IL-1, and IL-6 levels. In a recent study of 30 patients with cirrhosis and MHE, Jain *et al.*^[@bib19]^ found significant decrease in arterial ammonia and inflammatory mediators after 12 weeks of lactulose therapy.

However, while both MTR and PHES improved with treatment in MHE group, and ammonia, inflammatory markers, and PHES correlated with MTR at baseline, we could not demonstrate a correlation between changes in MTR values and changes in PHES, ammonia, or inflammatory markers to conclusively demonstrate the pathogenic role of neuroinflammation and cerebral edema in MHE. We believe this could be a type 2 error due to small number of MHE patients completing the study, and a larger sample size would be needed to demonstrate these correlations. Similarly, lack of significant improvement in ammonia and inflammatory markers with treatment in the MHE group also could be due to the small number of patients completing treatment.

Bilateral BG hyperintensities were common (60.8%) in patients with cirrhosis in our study and were more common in the MHE group (78.6%) than in the NMHE (33.3%) group although not statistically significant. In an earlier study from our center, it was found in 80% patients with cirrhosis.^[@bib24]^ T1 hyperintensity is likely due to increased concentration of manganese in the central nervous system with a preferential deposition in the globus pallidus. Pallidus hyperintensity occurs secondary to portal-systemic shunting, as it is also seen in patients with portal-systemic collaterals secondary to portal thrombosis and normal liver function.^[@bib25]^ Diffuse atrophy of the brain on MRI was seen in 47.5% patients of cirrhosis in our study. In a study by Thuluvath *et al.*^[@bib26]^ it was seen in 45% of patients with cirrhosis and was significantly more common in alcoholics. Most of the patients in our study had alcoholic cirrhosis. The mechanism is not known, but it appears to be related to chronic porto-systemic shunting and ammonia exposure.

In early HE, early phases of astrocytic changes characterized by cytoplasmic hypertrophy, increased mitochondria, dense endoplasmic reticulum, and increased water content are seen. Increased water content decreases the amount of magnetization transfer by diluting the number of structural protons in tissues, which may explain the reduced MTR values.^[@bib27]^ Rovira *et al*.^[@bib28]^ showed that MTR values of normal appearing white matter in patients with liver cirrhosis and MHE were significantly lower than those in controls. There was a trend towards lower MTR values in the patients with MHE compared with the NMHE group.^[@bib28]^ A study using voxel-based approach in MTR demonstrated that, compared with controls, patients with cirrhosis without HE displayed significantly decreased MTR values in the basal ganglia and in the hemispheric white matter. The group with MHE had a significant MTR decrease in hemispheric white matter, deep gray matter, brainstem, and cerebellum while the group with OHE showed an MTR decrease in the entire brain compared with controls, suggesting that as grade of edema increases, more areas of brain get involved. However, the authors did not compare MTR between MHE and NMHE group.^[@bib29]^ We demonstrated that MTR in all regions of the brain were significantly lower in MHE patients than controls. To best of our knowledge, we are the first to demonstrate significantly lower MTR in PWM, IC, and BG regions of brain in the MHE compared with the NMHE group. This is indicative of a low-grade cerebral edema seen in patients with MHE and not with NMHE, demonstrating the anatomical basis of MHE to complement the proposed pathophysiological role of neuroinflammation in MHE. MTR values along with MRS abnormalities and NP tests tend to improve after liver transplantation.^[@bib30]^ We demonstrated that after treatment of MHE patients with rifaximin and lactulose for 8 weeks MTR values improved to levels similar to that of controls, suggesting significant improvement in cerebral edema and establishing the reversible nature of MHE at the anatomical level. IL-6 and ammonia levels had significant negative correlation with MTR only in cortical areas, suggesting that with reduction in inflammation (IL-6) and ammonia there is a reduction in cerebral edema, and vice versa, in cortical white matter. Although studies have correlated ammonia and inflammatory mediators with MRS and DWI/DTI, there is no previous study correlating these parameters with MTR values.^[@bib19],\ [@bib31]^

We also demonstrated the clinical counterpart of improved MTR in the form of significant positive correlation of PHES with MTR. To the best of our knowledge, there is no study that correlated PHES or other neurophysiological tests with MTR values to substantiate our findings. However, there are few studies to show that cognitive domains as tested by various neurophysiological methods are selectively affected in MHE and correlate with MRS and DTI matrices.^[@bib19],\ [@bib32]^ The clinical significance of this study lies in that MTR may be a completely objective quantitative tool while PHES and other NP testing systems have an element of subjectivity to them. Thus MTR may be used for the diagnosis and follow-up of early neurological changes in patients with cirrhosis in future studies on the treatment of patients with cirrhosis with MHE.

As this study did not have a no-treatment arm in the MHE group, we cannot say for certain that the improvement in various parameters were due to the treatment or occurred spontaneously. However, this study did not aim to assess the efficacy of treatment in MHE but to demonstrate the pathology and reversibility of MHE at the anatomical and physiological level. We also did not study patients with OHE to see whether similar reversible MRI changes are also seen in them as part of this study. The importance of MTR changes in OHE could be the subject of further studies.

In conclusion, this study has demonstrated that MTR detects low-grade cerebral edema in MHE patients, which correlates with ammonia and inflammatory markers. Cerebral edema is reversible after treatment. MTR may be used as an objective surrogate end point in future trials assessing the efficacy of treatment of MHE.

Study Highlights
================
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![Flow of the patients into the study. MHE, minimal hepatic encephalopathy; MRI, magnetic imaging resonance; NMHE, no minimal hepatic encephalopathy; PHES, psychometric hepatic encephalopathy score.](ctg201538f1){#fig1}

###### Clinical and demographic characteristics of patients

  **Parameters**                         **Controls**                    **NMHE**                 **MHE**          ***P*** **value**
  -------------------------------------- ----------------------- ------------------------ ------------------------ -------------------
  *N*                                    6                                  9                        14             
  Age ( in years)                        47.5 (31.75 to 55.25)    47.00 (40.00 to 56.00)   49.50 (34.75 to 55.00)  0.855
  Sex (male: female)                     5:1                               8:1                      11:3           0.814
  *Etiology*                                                                                                        
   Alcohol                               ---                            4 (44.4%)                9 (64.3%)         0.417
   HBV                                   ---                            1 (11.1%)                 1 (7.1%)         1.000
   Alcohol+HBV                                                            0 (0%)                  1 (7.1%)         1.000
   HCV                                   ---                            2 (22.2%)                 1 (7.1%)         0.538
   NASH                                  ---                            1 (11.1%)                 1 (7.1%)         1.000
   Others                                ---                            1 (11.1%)                 1 (7.1%)         1.000
   Previous gastrointestinal bleed (%)   ---                             1 (11.1)                 3 (21.4)         0.448
   Previous decompensation               ---                             7 (77.8)                13 (92.9)         0.295
   Previous HE                           ---                             1 (11.1)                 5 (35.7)         0.190
   Diabetes mellitus                     ---                             2 (22.2)                 3 (21.4)         0.964
   Hypertension                          ---                             2 (22.2)                 1 (7.1)          0.295
   Creatinine (mg/dl)                    ---                       0.90 (0.75 to 1.18)      0.95 (0.90 to 1.12)    0.689
   Na^+^ (mEq/l)                         ---                      138.0 (136.0 to 141.0)   136.0 (135.0 to 141.5)  0.754
   CTP score                             ---                        10.0 (7.0 to 10.5)       10.5 (9.0 to 11.2)    0.197
   Child class A/B/C (%)                 ---                      1/3/5 (11.1/33.3/55.6)    0/4/10 (0/28.5/71.5)   0.405
   MELD score                            ---                         12.00 (11 to 25)       18.50 (16.7 to 22.5)   0.230
   PHES score                            2.0 (1.7 to 3.7)           −1.0 (−3.0 to 0.0)      −7.5 (−9.0 to −6.0)    \<0.001

CTP, Child--Turcotte--Pugh; HBV, hepatitis B virus; HCV, hepatitis C virus; HE, hepatic encephalopathy; MELD model of end-stage liver disease; MHE, minimal hepatic encephalopathy; NASH, non-alcoholic steatohepatitis; NMHE, no minimal hepatic encephalopathy; PHES, psychometric hepatic encephalopathy score. Data are expressed as median (25th--75th percentile range) or number (%).

###### Baseline arterial ammonia and IL-1, IL-6, and TNF-α in the study population

  **Parameters**                    **Controls (a)**               **NMHE (b)**                   **MHE (c)**           ***P*** **value a vs. b**   ***P*** **value b vs. c**   ***P*** **value a vs. c**
  -------------------------- ------------------------------ --------------------------- ------------------------------- --------------------------- --------------------------- ---------------------------
  *N*                         6[a](#t2-fn2){ref-type="fn"}               9               14[a](#t2-fn2){ref-type="fn"}                                                           
  SIRS                                     0%                           0%                          7 (50%)             ---                         0.019                       0.051
  Arterial ammonia (μg/dl)         37.50 (30.2--41.5)           51.00 (48.0--82.5)            98.0 (85.2--117.5)        0.024                       0.003                       \<0.001
  IL-1 (pg/ml)                     2.56 (2.08--16.29)          23.45 (13.79--42.25)          28.46 (17.49--49.90)       0.053                       0.382                       0.027
  IL-6 (pg/ml)                    31.47 (29.07--98.23)         63.65 (39.34--65.05)          69.03 (51.94--558.85)      0.147                       0.382                       0.045
  TNF-α (pg/ml)                2153.19 (1492.59--2568.58)    1985.24 (954.04--2354.72)    1682.93 (1174.61--2264.03)    0.463                       0.776                       0.461

IL-1, interleukin 1; MHE, minimal hepatic encephalopathy; NMHE, no minimal hepatic encephalopathy; SIRS, systemic inflammatory response syndrome; TNF-α, tumor necrosis factor alpha. Data are expressed as median (25th--75th percentile range) or numbers (%).

IL-1, IL-6, and TNF-α values are not available in 1 patient in the control group and 2 patients in the MHE group.

###### Arterial ammonia, inflammatory markers and PHES in the NMHE and MHE groups at baseline and after 8 weeks

  **Parameters**             **NMHE**                        **MHE**                                                                                                       
  -------------------------- ------------------------------- --------------------------------- ------- --------------------------------- --------------------------------- -------
  *N*                        7                               7                                         7                                 7                                  
  Arterial ammonia (μg/dl)   51.0 (48.0 to 72.5)             54.0 (44.0 to 65.0)               0.735   93.0 (74.7 to 102.5)              48.0 (42.0 to 106.0)              0.176
  IL-1 (pg/ml)               15.93 (12.48 to 39.33)          28.47 (16.66 to 50.92)            0.866   23.81 (12.89 to 45.31)            20.52 (16.76 to 23.45)            0.249
  IL-6 (pg/ml)               62.96 (39.00 to 65.71)          32.15 (29.42 to 60.91)            0.128   62.02 (35.58 to 156.00)           40.03 (21.88 to 71.18)            0.063
  TNF-α (pg/ml)              1,985.24 (957.40 to 2,464.45)   2,182.30 (1,644.86 to 2,193.49)   0.866   1,685.17 (1,174.61 to 2,264.03)   1,597.84 (1,252.99 to 1,774.74)   0.917
  PHES                       −1.0 (−2.0 to 0.0)              0.0 (−3.0 to 0.0)                 0.564   −6.5 (−8.7 to −6.0)               −4.0 (−6.0 to −3.0)               0.044

IL-1, interleukin 1; MHE, minimal hepatic encephalopathy; NMHE, no minimal hepatic encephalopathy; PHES, psychometric hepatic encephalopathy score; TNF-α, tumor necrosis factor alpha. Data are expressed in median (25th--75th percentile range).

###### Magnetization transfer ratio findings at baseline in the study population

  **Parameters**   **Controls (a)**          **NMHE (b)**              **MHE (c)**               ***P* value a vs. b**   ***P* value b vs. c**   ***P* value a vs. c**
  ---------------- ------------------------- ------------------------- ------------------------- ----------------------- ----------------------- -----------------------
  *N*              6                         8                         13                                                                         
  FWM              25.789 (24.071--26.835)   23.313 (21.330--29.824)   21.743 (19.342--23.095)   0.245                   0.105                   0.002
  PWM              25.227 (24.290--27.465)   23.987 (23.657--29.498)   21.687 (18.667--23.053)   0.573                   0.001                   0.002
  IC               26.383 (23.387--28.011)   24.410 (20.946--25.998)   20.776 (18.738--21.706)   0.345                   0.013                   0.003
  BG               20.353 (18.367--22.708)   20.590 (16.330--23.634)   18.124 (13.316--19.135)   1.000                   0.031                   0.019

BG, basal ganglia; FWM, frontal white matter; IC, internal capsule; MHE, minimal hepatic encephalopathy; NMHE, no minimal hepatic encephalopathy; PWM, parietal white matter. Data expressed in median (25th--75th percentile range). In one patient each in the NMHE and MHE groups, magnetization transfer ratio study was suboptimal and hence was excluded.

###### Magnetization transfer ratio in the NMHE and MHE groups at baseline and 8 weeks

        **Control**               **NMHE**                  **MHE**                                                                                       
  ----- ------------------------- ------------------------- ------------------------- ------- ------------------------- ------------------------- ------- -------
  *N*   6                         7                         7                                 7                         7                                  
  FWM   25.789 (24.071--26.835)   23.100 (20.686--31.992)   23.165 (22.973--25.402)   0.398   21.110 (20.740--22.736)   24.720 (20.874--28.203)   0.028   0.612
  PWM   25.227 (24.290--27.465)   23.890 (23.600--30.937)   23.529 (21.014--24.353)   0.063   21.687 (20.690--23.470    24.459 (21.909--25.760)   0.043   0.248
  IC    26.383 (23.387--28.011)   24.550 (20.286--26.450)   23.649 (19.642--25.540)   0.499   20.776 (20.180--22.190)   24.290 (21.233--27.931)   0.028   0.381
  BG    20.353 (18.367--22.708)   20.967 (16.040--23.652)   18.159 (16.900--19.354)   0.237   18.124 (14.020--18.629)   17.990 (15.072--23.831)   0.398   0.368

BG, basal ganglia; FWM, frontal white matter; IC, internal capsule; MHE, minimal hepatic encephalopathy; NMHE, no minimal hepatic encephalopathy; PWM, parietal white matter. Data expressed in median (25th--75th percentile range).
